Cargando…

Performance of Afirma genomic sequencing classifier and histopathological outcome are associated with patterns of atypia in Bethesda category III thyroid nodules

BACKGROUND: Data on Afirma’s genomic sequencing classifier (GSC) performance in atypia of undetermined significance (AUS) subcategories is limited. This study investigated GSC performance in AUS nodules with architectural atypia (AUS‐A), cytological atypia (AUS‐C), architectural and cytological atyp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Xiaobing, Lew, Madelyn, Pantanowitz, Liron, Smola, Brian, Jing, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796557/ https://www.ncbi.nlm.nih.gov/pubmed/35789120 http://dx.doi.org/10.1002/cncy.22625

Ejemplares similares

A Study of Thyroid Fine Needle Aspiration of Follicular Adenoma in the “Atypia of Undetermined Significance” Bethesda Category Using Digital Image Analysis
por: Yao, Keluo, et al.
Publicado: (2022)

Evaluation of thyroid nodules classified as Bethesda category III on FNAC
por: Garg, Shiwani, et al.
Publicado: (2017)

Predictors of Malignancy in Thyroid Nodules Classified as Bethesda Category III
por: Liu, Xiaoli, et al.
Publicado: (2022)

Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules
por: Hu, Mimi I, et al.
Publicado: (2021)

Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes
por: Baca, Sylvan C., et al.
Publicado: (2017)

Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience
por: Almahari, Sayed Ali, et al.
Publicado: (2019)

Malignancy rates in thyroid nodules classified as Bethesda categories III and IV; a subcontinent perspective
por: Zahid, Adnan, et al.
Publicado: (2021)

Surgical Outcome and Malignant Risk Factors in Patients With Thyroid Nodule Classified as Bethesda Category III
por: Huang, Jianhao, et al.
Publicado: (2021)

Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3
por: Kim, Na Eun, et al.
Publicado: (2023)

Thyroid Cancer Detection Rate and Associated Risk Factors in Patients with Thyroid Nodules Classified As Bethesda Category III
por: Mileva, Magdalena, et al.
Publicado: (2018)

LBODP107 Real World Performance Of The Afirma Xpression Atlas In Bethesda III And IV Thyroid Nodules. A Private Practice Experience
por: Ortega, Dayron, et al.
Publicado: (2022)

Repeat Diagnoses of Bethesda Category III Thyroid Nodules: What To Do Next?
por: Yoo, Mi Ri, et al.
Publicado: (2015)

Malignancy Rates in Thyroid Nodules Classified as Bethesda Categories III and IV: Retrospective Data from a Tertiary Center
por: Godoi Cavalheiro, Beatriz, et al.
Publicado: (2017)

AI diagnosis of Bethesda category IV thyroid nodules
por: Yao, Jincao, et al.
Publicado: (2023)

Intraoperative frozen section can be reduced in thyroid nodules classified as Bethesda categories V and VI
por: Huang, Jing, et al.
Publicado: (2017)

Effective Use of microRNA, BRAF and Sonographic Risk Assessment in Bethesda III Thyroid Nodules Requires a Different Approach to Nodules with Features of Nuclear Atypia and Other Types of Atypia
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2023)

Hashimoto’s Thyroiditis Does Not Influence the Malignancy Risk in Nodules of Category III in the Bethesda System
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2022)

Malignancy in Thyroid Nodules with Bethesda III Category on Repeat Fine Needle Aspiration Biopsy*
por: Lourdes Ng, Jennifer, et al.
Publicado: (2023)

Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital
por: Al Dawish, Mohamed, et al.
Publicado: (2020)

Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?
por: Turkdogan, Sena, et al.
Publicado: (2020)

The Prediction of Malignancy Risk in Thyroid Nodules Classified as Bethesda System Category III (AUS/FLUS) and the Role of Ultrasound Finding for Prediction of Malignancy Risk
por: Alshahrani, Awad S, et al.
Publicado: (2021)

The Diagnostic Performance of Afirma Gene Expression Classifier for the Indeterminate Thyroid Nodules: A Meta-Analysis
por: Liu, Ying, et al.
Publicado: (2019)

Analytical Verification Performance of Afirma Genomic Sequencing Classifier in the Diagnosis of Cytologically Indeterminate Thyroid Nodules
por: Hao, Yangyang, et al.
Publicado: (2019)

Thyroid Nodules Cytopathology Applying the Bethesda System with Histopathological Correlation
por: Zarif, Hawazen A., et al.
Publicado: (2018)

Molecular Profiling of Thyroid Nodules: Current Role for the Afirma Gene Expression Classifier on Clinical Decision Making
por: Kloos, Richard T.
Publicado: (2017)

Malignancy rate of Bethesda category III thyroid nodules according to ultrasound risk stratification system and cytological subtype
por: Yoo, Won Sang, et al.
Publicado: (2020)

Clinico-cytopathological subcategorization in thyroid nodules of atypia of undetermined significance/follicular lesion of undetermined significance using the TIRADS and Bethesda classifications
por: Babajani, Amirhesam, et al.
Publicado: (2023)

Shear wave elastography and Afirma™ gene expression classifier in thyroid nodules with indeterminate cytology: a comparison study
por: Azizi, Ghobad, et al.
Publicado: (2018)

Radiofrequency ablation for thyroid Bethesda III nodules: preliminary results
por: Chiang, Pi-Ling, et al.
Publicado: (2023)

Evaluation of selected ultrasound features of thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance for the Bethesda reporting system for thyroid cytology
por: Kaliszewski, Krzysztof, et al.
Publicado: (2018)

Use of the Afirma® Gene Expression Classifier for Preoperative Identification of Benign Thyroid Nodules with Indeterminate Fine Needle Aspiration Cytopathology
por: Ali, Syed Z., et al.
Publicado: (2013)

MON-518 Institutional Experience with Cytologically Indeterminate Thyroid Nodules: No Molecular Testing Versus Afirma Gene Expression Classifier or Genomic Sequencing Classifier
por: Polavarapu, Preethi, et al.
Publicado: (2020)

Prospective Study of Bethesda Categories III and IV Thyroid Nodules: Outcomes and Predictive Value of BRAF(V600E) Mutation
por: Chirayath, Shiga Rappai, et al.
Publicado: (2019)

The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III (Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance) by Thyroid Fine‐Needle Aspiration Could Be Assisted by Tumor Size for Precision Treatment
por: Zha, Xiaojuan, et al.
Publicado: (2022)

Comparison of Afirma GEC and GSC to Nodules Without Molecular Testing in Cytologically Indeterminate Thyroid Nodules
por: Polavarapu, Preethi, et al.
Publicado: (2021)

The impact of thyroid imaging reporting and data system on the management of Bethesda III thyroid nodules()
por: Alqahtani, Saad M., et al.
Publicado: (2022)

Corrigendum: The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III (Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance) by Thyroid Fine‐Needle Aspiration Could Be Assisted by Tumor Size for Precision Treatment
por: Zha, Xiaojuan, et al.
Publicado: (2022)

Histopathological Review of Diagnostic Categories of the Bethesda System for Reporting Thyroid Cytopathology – An Institutional Experience of 5 Years
por: Upadhyaya, Paricha, et al.
Publicado: (2019)

The Role of “Critical” Ultrasound Reassessment in the Decision-Making of Bethesda III Thyroid Nodules
por: Orlando, Giuseppina, et al.
Publicado: (2023)

Concordance of the ACR TI-RADS Classification With Bethesda Scoring and Histopathology Risk Stratification of Thyroid Nodules
por: Huang, Elaine Y. F., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kf9u73ap9eeesleg70f7ls3roe